CTNM Contineum Therapeutics, Inc.

Nasdaq www.contineum-tx.com


$ 11.05 $ 0.00 (0 %)    

Monday, 27-Oct-2025 07:57:14 EDT
QQQ $ 624.72 $ 0.00 (0 %)
DIA $ 474.30 $ 0.00 (0 %)
SPY $ 682.51 $ 0.00 (0 %)
TLT $ 91.17 $ 0.00 (0 %)
GLD $ 371.00 $ 0.00 (0 %)
$ 11.05
$ 11.05
$ 11.05 x 50
$ 11.30 x 300
-- - --
$ 3.35 - $ 20.24
50,838
na
309.86M
$ 0.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-16-2024 03-31-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 this-lululemon-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 this-biogen-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Core News & Articles

Leerink Partners analyst Faisal Khurshid initiates coverage on Contineum Therapeutics (NASDAQ: CTNM) with a Outperform ratin...

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Overweight and raises the price ta...

Core News & Articles

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate...

Core News & Articles

Contineum Therapeutics, Inc.

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Overweight and lowers the price ta...

Core News & Articles

RBC Capital analyst Brian Abrahams reiterates Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and maintains $31 price...

Core News & Articles

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate...

Core News & Articles

Jones Trading analyst Debanjana Chatterjee initiates coverage on Contineum Therapeutics (NASDAQ:CTNM) with a Buy rating and ...

Core News & Articles

Morgan Stanley analyst Jeffrey Hung assumes Contineum Therapeutics (NASDAQ:CTNM) with a Overweight rating and maintains Pric...

Core News & Articles

Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lowers the price target from ...

Core News & Articles

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate...

Core News & Articles

- Exploratory phase 1b trial will evaluate safety, tolerability and effect on pain intensity- Topline data readout planned for ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION